The integration of Fusion with FactSet was prompted by J.P. Morgan's institutional clients, who wanted to receive J.P. Morgan data using modern technology, according to Jason Mirsky, J.P. Morgan ...
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback